Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy (RESET-HA)

  • End date
    Sep 22, 2024
  • participants needed
  • sponsor
    Tremeau Pharmceuticals, Inc.
Updated on 7 October 2022


This is a multicenter, randomized, double-blind study to evaluate the efficacy and safety of TRM-201 (rofecoxib) versus Placebo in the treatment of patients with hemophilic arthropathy (HA) over a 12-week period (Part I) that is followed by a year-long (52 week) open-label extension (Part II) to further evaluate the safety and maintenance of efficacy of TRM-201.

Condition Hemophilic Arthropathy
Treatment Placebo, TRM-201 (Rofecoxib)
Clinical Study IdentifierNCT04684511
SponsorTremeau Pharmceuticals, Inc.
Last Modified on7 October 2022


Yes No Not Sure

Inclusion Criteria

Diagnosis of hemophilia A or B
Either on a stable prophylaxis regimen for their bleeding disorder (factor, bypassing agent, or nonfactor product therapy) OR currently taking or agree to initiate a gastroprotective agent (esomeprazole) for the duration of the trial
Diagnosis of Hemophilic Arthopathy for at least 6 months prior to screening
Chronic symptomatic pain in one or more joint(s) on 20 of the 30 days prior to screening
Able and willing to wash out of non-study analgesic medications/agents for at least 7 days prior to Randomization including: acetaminophen (paracetamol), NSAIDs, opioids, cannabinoids, topical analgesics, benzodiazepines, gabapentin/pregabalin-containing products and other antiepileptic drugs used for pain
Primary source of pain is due to Hemophilic Arthropathy

Exclusion Criteria

Taking opioids for greater than 4 days per week prior to screening
Has a history of advanced renal disease or severe liver disease (within the last 6 months)
Receiving emicizumab while also receiving activated prothrombin complex concentrate (FEIBA)
Uncontrolled or poorly controlled hypertension
History of major cardiac or cerebrovascular disease
History of an upper GI perforation, obstruction, or major GI bleed or current evidence of GI bleeding
Has active hepatitis C or hepatitis B infection or uncontrolled HIV. Note: Patients who are HIV positive are allowed to participate if considered to be controlled
Has a positive drug screen for all prohibited drugs of potential abuse at screening
Has had an intra-articular injection (within 3 months), initiated physical therapy (within 30 days) or has had orthopedic surgery (within 4 months) prior to screening
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note